News:
Treventis attends the 2nd Neuromuscular Drug Development Summit (NMD)
CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are...
Read More
Treventis attends the 2nd Neuromuscular Drug Development Summit (NMD)
CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are...
Read More
News:
Treventis attends the 2nd Neuromuscular Drug Development Summit (NMD)
CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are...
Read More
Treventis attends the 2nd Neuromuscular Drug Development Summit (NMD)
CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are...
Read More
TREVENTIS™ utilizes a proprietary, patented discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets.
CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets.
Our Takeda-partnered lead program focuses on anti-misfolding small molecules in Alzheimer’s disease. We have further CCM-driven, U.S. DOD-funded efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.
Treventis has active
druggable CCM models for
Tau
Alpha Synuclein
p53
Amylin
And the Potential to Make 160+ Others…
